<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469169</url>
  </required_header>
  <id_info>
    <org_study_id>15503</org_study_id>
    <nct_id>NCT01469169</nct_id>
  </id_info>
  <brief_title>Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study</brief_title>
  <acronym>IBUKI</acronym>
  <official_title>A Multi-center, Non-randomized, Open Label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of BAY q 6256 (Iloprost) Inhalation in Patients With Pulmonary Arterial Hypertension (PAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the efficacy, safety, and Pharmacokinetics (PK) of Inhaled
      Iloprost (Ventavis) therapy in Japanese pulmonary arterial hypertension (PAH) patients in
      Main Treatment Phase (12 weeks) and to investigate the safety, tolerability, and efficacy of
      longterm Inhaled Iloprost (Ventavis) therapy in Japanese PAH patients in Extension Phase.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2012</start_date>
  <completion_date type="Actual">December 14, 2016</completion_date>
  <primary_completion_date type="Actual">December 26, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pulmonary vascular resistance (PVR) from screening (baseline) to week 12 (after inhalation)</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Up to 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration vs time curve from start of inhalation to infinity after single inhalation (AUC)</measure>
    <time_frame>At baseline, 12 weeks, 52 weeks and over 52 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum drug concentration in plasma after start of inhalation (Cmax)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Over 52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Pulmonary vascular resistance index (PVRI) from baseline to week 12</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of mean of pulmonary artery pressure from baseline to week 12</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of systolic pulmonary artery pressure from baseline to week 12</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of diastolic pulmonary artery pressure from baseline to week 12</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean right atrial pressure (RAPm)</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulmonary capillary wedge pressure (PCWP)</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac output (CO)</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean arterial pressure (MAP)</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Mixed venous oxygen saturation (SVO2)</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic vascular resistance (SVR)</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic vascular resistance index (SVRI)</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac index</measure>
    <time_frame>At baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute walking test (6MWT)</measure>
    <time_frame>At baseline, 12 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Borg CR 10 Score</measure>
    <time_frame>At baseline, 12 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association/ World Health Organization (NYHA/WHO) class</measure>
    <time_frame>At baseline, 12 weeks, 52 weeks and over 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in N-terminal pro-B-type natriuretic peptide (NT-ProBNP)</measure>
    <time_frame>At baseline, 12 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EQ-5D and Living with Pulmonary Hypertension (LPH) questionnaires</measure>
    <time_frame>At baseline, 12 weeks and 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical worsening during the study</measure>
    <time_frame>At baseline, 12 weeks, 52 weeks and over 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality during the study</measure>
    <time_frame>At baseline, 12 weeks, 52 weeks and over 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for transplantation during the study</measure>
    <time_frame>At baseline, 12 weeks, 52 weeks and over 52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC from time start of inhalation to the last data point AUC(0-tlast)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC divided by dose per kg body weight (AUCnorm)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC divided by dose (μg) (AUC/D)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum drug concentration in plasma after start of inhalation divided by dose (μg) per kg body weight (Cmax,norm)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum drug concentration in plasma after start of inhalation divided by dose (μg) (Cmax/D)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum drug concentration in plasma after start of inhalation (tmax )</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life associated with the terminal slope (t1/2)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iloprost (Ventavis inhaled, BAYQ6256)</intervention_name>
    <description>2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged 18 to 75 years

          -  Symptomatic Pulmonary Artery Hypertension (PAH) classified (Dana Point Classification
             1)

          -  New York Heart Association (NYHA)/World Health Organization (WHO) functional class III
             or IV

          -  PAPmean at rest &gt; 25 mm Hg, Pulmonary capillary wedge pressure (PCWP) or left
             ventricular end-diastolic pressure &lt;/= 15 mm Hg and Pulmonary Vascular resistance
             (PVR) &gt;/= 240 dyn.sec.cm-5 (&gt;/= 400 dyn.sec.cm-5 for patients treated with both
             endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE5i) ) as
             measured by Right Heart Catheter test

          -  Women of childbearing potential and men must agree to use adequate contraception when
             sexually active

        Exclusion Criteria:

          -  Baseline 6-minute walk distance of less than 100 meters or more than 500 meters

          -  Subjects with critical severe PAH

          -  Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio &lt; 60%
             and/or Total Lung Capacity (TLC) &lt; 70% predicted (especially at interstitial lung
             disease, TLC &lt; 60% predicted)

          -  Clinically relevant obstructive lung disease (e.g. asthma or chronic obstructive
             pulmonary disease )

          -  More than mild patchy interstitial lung disease on High Resolution Computerized
             Tomography (HRCT)

          -  History of left-sided heart disease

          -  Uncontrolled systemic hypertension as evidenced by systolic blood pressure &gt;/= 160 mm
             Hg or diastolic blood pressure &gt;/= 100 mm Hg on repeated measurement

          -  Systemic hypotension with systolic blood pressure &lt; 85 mm Hg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asahikwa</city>
        <state>Hokkaido</state>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomigusuku</city>
        <state>Okinawa</state>
        <zip>901-0243</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuoku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-8541</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tanabe</city>
        <state>Wakayama</state>
        <zip>646-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/</url>
    <description>Click here to find results for studies related to Bayer products.</description>
  </link>
  <results_reference>
    <citation>Saji T, Myoishi M, Sugimura K, Tahara N, Takeda Y, Fukuda K, Olschewski H, Matsuda Y, Nikkho S, Satoh T. Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension - Insights From the IBUKI and AIR Studies. Circ J. 2016;80(4):835-42. doi: 10.1253/circj.CJ-16-0097. Epub 2016 Mar 18.</citation>
    <PMID>27001191</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2011</study_first_submitted>
  <study_first_submitted_qc>November 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iloprost</keyword>
  <keyword>Inhalation</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Pulmonary Artery Hypertension</keyword>
  <keyword>Japanese Patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iloprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

